Zika virus seroprevalence in blood donors from the Northeastern region of São Paulo State, Brazil, between 2015 and 2017

Slavov, Svetoslav Nanev; Machado, Rafael Rahal Guaragna; Ferreira, A. R.; Soares, Camila Pereira; Araújo, Danielle Bastos; Oliveira, Danielle Bruna Leal; Covas, Dimas Tadeu; Durigon, Edison Luiz; Kashima, Simone

doi:10.1016/j.jinf.2019.10.002

Cited by 10 publications

(6 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…While it caused a major outbreak since May 2015 in Brazil, then fast spread over all America. However, a study showed that blood donor samples collected in March 2015 from the state of São Paulo, the southeast region of Brazil, was positive for the nucleic acid of the virus ( Slavov et al, 2020 ). Similarly, in Colombia, the first registered confirmed Zika virus infected case was reported in October 2015.…”

Section: Discussionmentioning

confidence: 99%

Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

et al. 2022

View full text Add to dashboard Cite

The emerging of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused COVID-19 pandemic. The first case of COVID-19 was reported at early December in 2019 in Wuhan city, China. To examine specific antibodies against SARS-CoV-2 in biological samples before December 2019 would give clues when the epidemic of SARS-CoV-2 might start to circulate in populations. We obtained all 88,517 plasmas from 76,844 blood donors in Wuhan between 1st September and 31st December 2019. We first evaluated the pan-immunoglobin (pan-Ig) against SARS-CoV-2 in 43,850 samples from 32,484 blood donors with suitable sample quality and enough volume. 264 samples from 213 donors were pan-Ig reactive, then further tested IgG and IgM, and validated by neutralizing antibodies against SARS-CoV-2. 213 samples (from 175 donors) were only pan-Ig reactive, 8 (from 4 donors) were pan-Ig and IgG reactive and 43 (from 34 donors) were pan-Ig and IgM reactive. Microneutralization assay showed all negative results. In addition, 213 screened reactive donors were analyzed and didn’t show obviously temporal or regional tendency, but the distribution of age showed a difference compared with all tested donors. Then we reviewed SARS-CoV-2 antibody results from these donors who donated several times from September 2019 to June 2020, partly tested in a previous published study, no one was found a significant increase in S/CO of antibodies against SARS-CoV-2. Our findings showed no SARS-CoV-2 specific antibodies existing among blood donors in Wuhan, China before 2020, indicating no evidence of transmission of COVID-19 before December 2019 in Wuhan, China.

show abstract

Section: Discussionmentioning

confidence: 99%

Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The transfusion community has faced epidemics and pandemics before [2][3][4][5][6][7][8][9], but little has been published about the preparations made by hospital-based transfusion services for handling samples and performing pre-transfusion testing on patients who are affected by the disease. A study of the policies and procedures vis-a-vis pre-transfusion testing and the provision of blood products at three Japanese hospitals during the recent Ebola epidemic revealed different approaches to performing pre-transfusion testing on potential recipients and how the blood products were issued [10].…”

Section: Introductionmentioning

confidence: 99%

Vox Sanguinis International Forum on transfusion services' response to COVID‐19: Summary

et al. 2020

View full text Add to dashboard Cite

“…The most commonly used method, the indirect semi-quantitative NS1 ELISA IgG, was preferred due to its higher sensitivity, stronger response, longer duration of detectability, and reduced cross-reactivity compared to the envelope protein E, which is highly conserved and leads to suboptimal diagnoses [ 58 ]. However, significant cross-reactivity persists, as demonstrated in a study in Brazil with 54.0% of cross-reactivity when compared with PRNT [ 59 ], and 60.0% in a study in Bolivia compared with VNT [ 1 ]. Nonetheless, significant advancements and investments have been made in the development and improvement of tests.…”

Section: Discussionmentioning

confidence: 99%

Global seroprevalence of Zika virus in asymptomatic individuals: A systematic review

Saba Villarroel,

Hamel,

Gumpangseth

et al. 2024

PLoS Negl Trop Dis

View full text Add to dashboard Cite

Background Zika virus (ZIKV) has spread to five of the six World Health Organization (WHO) regions. Given the substantial number of asymptomatic infections and clinical presentations resembling those of other arboviruses, estimating the true burden of ZIKV infections is both challenging and essential. Therefore, we conducted a systematic review and meta-analysis of seroprevalence studies of ZIKV IgG in asymptomatic population to estimate its global impact and distribution. Methodology/Principal findings We conducted extensive searches and compiled a collection of articles published from Jan/01/2000, to Jul/31/2023, from Embase, Pubmed, SciELO, and Scopus databases. The random effects model was used to pool prevalences, reported with their 95% confidence interval (CI), a tool to assess the risk of study bias in prevalence studies, and the I2 method for heterogeneity (PROSPERO registration No. CRD42023442227). Eighty-four studies from 49 countries/territories, with a diversity of study designs and serological tests were included. The global seroprevalence of ZIKV was 21.0% (95%CI 16.1%-26.4%). Evidence of IgG antibodies was identified in all WHO regions, except for Europe. Seroprevalence correlated with the epidemics in the Americas (39.9%, 95%CI:30.0–49.9), and in some Western Pacific countries (15.6%, 95%CI:8.2–24.9), as well as with recent and past circulation in Southeast Asia (22.8%, 95%CI:16.5–29.7), particularly in Thailand. Additionally, sustained low circulation was observed in Africa (8.4%, 95%CI:4.8–12.9), except for Gabon (43.7%), and Burkina Faso (22.8%). Although no autochthonous transmission was identified in the Eastern Mediterranean, a seroprevalence of 16.0% was recorded. Conclusions/Significance The study highlights the high heterogeneity and gaps in the distribution of seroprevalence. The implementation of standardized protocols and the development of tests with high specificity are essential for ensuring a valid comparison between studies. Equally crucial are vector surveillance and control methods to reduce the risk of emerging and re-emerging ZIKV outbreaks, whether caused by Ae. aegypti or Ae. albopictus or by the Asian or African ZIKV.

show abstract

Zika virus seroprevalence in blood donors from the Northeastern region of São Paulo State, Brazil, between 2015 and 2017

Cited by 10 publications

References 26 publications

Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

Serosurvey for SARS-CoV-2 among blood donors in Wuhan, China from September to December 2019

Vox Sanguinis International Forum on transfusion services' response to COVID‐19: Summary

Global seroprevalence of Zika virus in asymptomatic individuals: A systematic review

Contact Info

Product

Resources

About